Mode
Text Size
Log in / Sign up
N/A Completed N=34 Randomized Double-blind Treatment

A Bilateral Dispensing Clinical Trial of Sapphire Lens Against Senofilcon A Lens Over 2 Weeks

Source: ClinicalTrials.gov NCT02345811 ↗
Enrolled (actual)
34
Serious AEs
0.0%
Results posted
Sep 2020
Primary outcomePrimary: Vision Quality — 93; 94 units on a scale

Summary

To evaluate the clinical performance of an investigational silicone-hydrogel lens when worn on a daily wear modality over two weeks of lens wear.

Outcome Measures

OutcomeResultp-value
PRIMARY
Vision Quality
86; 87
PRIMARY
Vision Quality
86; 87
PRIMARY
Vision Quality
86; 87
PRIMARY
Subjective Rating for Comfort.
66; 81
PRIMARY
Subjective Rating for Comfort.
66; 81
PRIMARY
Subjective Rating for Comfort.
66; 81
PRIMARY
Lens Surface Wettability
3.0; 3.2
PRIMARY
Lens Surface Wettability
3.0; 3.2
PRIMARY
Surface Deposits
0.45; 0.40
PRIMARY
Surface Deposits
0.45; 0.40
PRIMARY
Lens Handling (Ease of Insertion)
93; 95
PRIMARY
Lens Handling (Ease of Removal)
90; 95
PRIMARY
Subjective Preference for Comfort.
23; 68; 9
PRIMARY
Subjective Preference for Comfort.
23; 68; 9

Eligibility Criteria

Inclusion Criteria

  • Is at least 17 years of age for Canada and 18 years of age for the USA and has full legal capacity to volunteer
  • Has read and signed an information consent letter
  • Is willing and able to follow instructions and maintain the appointment schedule;
  • Is an adapted soft contact lens wearer
  • Requires spectacle lens powers between -0.50 to -6.00 diopters sphere (0.25D steps) or +1.00 to +8.00 diopters sphere (1.00D steps)
  • Has no more than 0.75 diopters of refractive astigmatism
  • Willing to wear contact lens in both eyes
  • Has manifest refraction visual acuities (VA) equal to or better than logMAR equivalent of 20/25 in each eye
  • To be eligible for lens dispensing, the subject must have VA of logMAR equivalent of 20/30 or better in each eye with the study lenses and the investigator must judge the fit as acceptable

Exclusion Criteria

  • Is participating in any concurrent clinical or research study
  • Has any known active* ocular disease and/or infection
  • Has a systemic condition that in the opinion of the investigator may affect a study outcome variable
  • Is using any systemic or topical medications that in the opinion of the investigator may affect a study outcome variable
  • Has known sensitivity to the diagnostic pharmaceuticals to be used in the study
  • Is pregnant, lactating or planning a pregnancy at the time of enrolment (by verbal confirmation at the screening visit)
  • Is aphakic
  • Has undergone refractive error surgery
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02345811). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search